NASDAQ:NTRA - Natera Stock Price, News & Analysis

$28.26
+0.54 (+1.95 %)
(As of 08/18/2019 07:20 AM ET)
Today's Range
$26.94
Now: $28.26
$28.33
50-Day Range
$25.33
MA: $27.24
$33.05
52-Week Range
$11.08
Now: $28.26
$33.25
Volume471,700 shs
Average Volume752,806 shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$257.65 million
Book Value$1.33 per share

Profitability

Net Income$-128,150,000.00

Miscellaneous

Employees975
Market Cap$1.98 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.


Natera (NASDAQ:NTRA) Frequently Asked Questions

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) announced its quarterly earnings data on Wednesday, August, 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09. The medical research company had revenue of $74.36 million for the quarter, compared to analysts' expectations of $66.77 million. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The business's revenue for the quarter was up 17.9% on a year-over-year basis. During the same period last year, the firm earned ($0.62) earnings per share. View Natera's Earnings History.

When is Natera's next earnings date?

Natera is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Natera.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275-305 million, compared to the consensus revenue estimate of $288.5 million.

What price target have analysts set for NTRA?

6 brokers have issued 1-year target prices for Natera's shares. Their forecasts range from $26.00 to $41.00. On average, they expect Natera's share price to reach $33.6667 in the next year. This suggests a possible upside of 19.1% from the stock's current price. View Analyst Price Targets for Natera.

What is the consensus analysts' recommendation for Natera?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:
  • 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (8/9/2019)
  • 2. Canaccord Genuity analysts commented, "We reiterate Natera as one of our top picks for 2019, reiterate our Buy rating and raise our PT to $36. Q2. Q2/19 revs of $74.4M (+18% Y/Y) beat our $66M (+5%)/Street’s $66.8M, with the beat coming from a $5M payment from BGI. Y/Y) beat our 194.4k (+19%), with Panorama NIPT and Horizon carrier screening volume growth of +18% and +27% nearly matching our estimate. GM of 41% beat our 34%, helped by the BGI payment. Natera’s 20% Y/Y volume growth implies to us that this market leader is holding its ground quite nicely, despite noise in investor circles suggesting rising competition or declining pricing. Q2/19 rev/test increased q/q to $393 from $384. ACOG. Natera is in dialogue with folks at the highest level of ACOG and expect a positive new bulletin for average-risk NIPT." (8/8/2019)

Has Natera been receiving favorable news coverage?

Media coverage about NTRA stock has been trending negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Natera.

Are investors shorting Natera?

Natera saw a decrease in short interest in July. As of July 31st, there was short interest totalling 3,093,800 shares, a decrease of 27.5% from the June 30th total of 4,267,100 shares. Based on an average trading volume of 717,000 shares, the short-interest ratio is currently 4.3 days. Currently, 6.6% of the shares of the stock are sold short. View Natera's Current Options Chain.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Transocean (RIG), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ).

Who are Natera's key executives?

Natera's management team includes the folowing people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 40)
  • Mr. Michael Brophy, Chief Financial Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.05%), BlackRock Inc. (6.96%), Jennison Associates LLC (6.37%), Jennison Associates LLC (6.37%), Orbimed Advisors LLC (4.60%) and Invesco Ltd. (2.93%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

Which major investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Price T Rowe Associates Inc. MD, Essex Investment Management Co. LLC, A.R.T. Advisors LLC, Point72 Asset Management L.P., Morgan Stanley and Strs Ohio. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

Which major investors are buying Natera stock?

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BlackRock Inc., Invesco Ltd., Wells Fargo & Company MN, Nuveen Asset Management LLC, Jennison Associates LLC, Jennison Associates LLC and Vanguard Group Inc.. View Insider Buying and Selling for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $28.26.

How big of a company is Natera?

Natera has a market capitalization of $1.98 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

What is Natera's official website?

The official website for Natera is http://www.natera.com/.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]


MarketBeat Community Rating for Natera (NASDAQ NTRA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: What is an SEC Filing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel